High Expression of the Thalidomide-Binding Protein Cereblon (CRBN) Is Associated with Improved Clinical Response in Patients with Multiple Myeloma Treated with Lenalidomide and Dexamethasone

被引：3
|
作者：
Heintel, Daniel [1 ]
Bolomsky, Arnold [1 ]
Schreder, Martin [1 ]
Pfeifer, Sabine [1 ]
Zojer, Niklas [1 ]
Jaeger, Ulrich [2 ]
Ludwig, Heinz [1 ]
机构：
[1] Wilhelminenhosp, Ctr Oncol & Hematol, Dept Internal Med 1, Vienna, Austria
[2] Med Univ Vienna, Vienna, Austria
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
10.1182/blood.V118.21.2879.2879
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1242 / 1243
页数：2
相关论文
共 50 条
  • [31] THROMBOPHILIC ALTERATIONS AND RISK OF VENOUS THROMBOEMBOLISM IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH THALIDOMIDE AND HIGH-DOSE DEXAMETHASONE
    Zamagni, E.
    Valdre, L.
    Cini, M.
    Legnani, C.
    Tosi, P.
    Tacchetti, P.
    Ceccolini, M.
    Patriarca, F.
    Catalano, L.
    Casulli, A. F.
    Volpe, S.
    Perrone, G.
    Masini, L.
    Ledda, A.
    Falcioni, S.
    Brioli, A.
    Gozzetti, A.
    Califano, C.
    Pallotti, M. C.
    Cellini, C.
    Pantani, L.
    Petrucci, A.
    Carubelli, A.
    Baccarani, M.
    Palareti, G.
    Cavo, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 363 - 363
  • [32] Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy
    Kobayashi, Takahiro
    Fujioka, Yuki
    Ikeda, Sho
    Nishikawa, Hiroyoshi
    Takahashi, Naoto
    BLOOD, 2019, 134
  • [33] Clinical and Correlative Pilot Study Of Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Extended Dosing (CRd - R) In High Risk Smoldering Multiple Myeloma Patients
    Landgren, Ola
    Mailankody, Sham
    Kwok, Mary
    Manasanch, Elisabet E.
    Bhutani, Manisha
    Tageja, Nishant
    Kazandjian, Dickran
    Zingone, Adriana
    Costello, Rene
    Burton, Debra
    Zhang, Yong
    Wu, Peter
    Carter, George
    Mulquin, Marcia
    Zuchlinski, Diamond
    Maric, Irina
    Calvo, Katherine R.
    Braylan, Raul C.
    Yuan, Constance
    Stetler-Stevenson, Maryalice
    Arthur, Diane C.
    Lindenberg, Liza
    Kurdziel, Karen
    Choyke, Peter
    Steinberg, Seth M.
    Roschewski, Mark
    Korde, Neha
    BLOOD, 2013, 122 (21)
  • [34] High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
    Maryam Pourabdollah
    Mohammad Bahmanyar
    Eshetu G. Atenafu
    Donna Reece
    Jian Hou
    Hong Chang
    Journal of Hematology & Oncology, 9
  • [35] High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide
    Pourabdollah, Maryam
    Bahmanyar, Mohammad
    Atenafu, Eshetu G.
    Reece, Donna
    Hou, Jian
    Chang, Hong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [36] Correlation between eight-gene expression profiling and response to therapy of newly diagnosed multiple myeloma patients treated with thalidomide–dexamethasone incorporated into double autologous transplantation
    Carolina Terragna
    Matteo Renzulli
    Daniel Remondini
    Enrico Tagliafico
    Francesco Di Raimondo
    Francesca Patriarca
    Giovanni Martinelli
    Enrica Roncaglia
    Luciano Masini
    Patrizia Tosi
    Elena Zamagni
    Paola Tacchetti
    Antonio Ledda
    Annamaria Brioli
    Emanuele Angelucci
    Nicoletta Testoni
    Giulia Marzocchi
    Piero Galieni
    Alessandro Gozzetti
    Marina Martello
    Flores Dico
    Katia Mancuso
    Michele Cavo
    Annals of Hematology, 2013, 92 : 1271 - 1280
  • [37] Baseline thrombophilic alterations and risk of venous thromboembolism in 266 multiple myeloma patients primarily treated with thalidomide and high-dose dexamethasone
    Zamagni, Elena
    Valdre, Lelia
    Cini, Michela
    Legnani, Cristina
    Tosi, Patrizia
    Tacchetti, Paola
    Patriarca, Francesca
    Ceccolini, Michela
    Catalano, Lucio
    Favaretto, Elisa
    Casulli, Francesco
    Volpe, Silvestro
    Perrone, Giulia
    Masini, Luciano
    Ledda, Antonio
    Falcioni, Sadia
    Brioli, Annamaria
    Gozzetti, Alessandro
    Califano, Catello
    Pallotti, Mariacaterina
    Cellini, Claudia
    Carubelli, Affra
    Pantani, Lucia
    Baccarani, Michele
    Palareti, Gualtiero
    Cavo, Michele
    BLOOD, 2007, 110 (11) : 67B - 68B
  • [38] The Role of 18f-FDG-PET/CT in Characterizing Depth of Response in High Risk Smoldering Multiple Myeloma Patients Treated with Carfilzomib, Lenalidomide, and Dexamethasone (KRd)
    Hill, Elizabeth
    Korde, Neha
    Morrison, Candis
    Dew, Alexander
    Carpenter, Ashley
    Epstein, Monica
    Lu, Crystal
    Choyke, Peter
    Mena, Esther
    Lindenberg, Liza
    Landgren, Ola
    Kazandjian, Dickran
    BLOOD, 2020, 136
  • [39] Stringent complete response (sCR) in patients (pts) with newly diagnosed multiple myeloma (NDMM) treated with carfilzomib (CFZ), lenalidomide (LEN), and dexamethasone (DEX).
    Jakubowiak, Andrzej J.
    Griffith, Kent A.
    Dytfeld, Dominik
    Vesole, David H.
    Jagannath, Sundar
    Anderson, Tara B.
    Nordgren, Brian K.
    Detweiler-Short, Kristen
    Lebovic, Daniel
    Stockerl-Goldstein, Keith
    Jobkar, Terri L.
    Wear, Sandra Marija
    Al-Zoubi, Ammar
    Ahmed, Asra Z.
    Mietzel, Melissa A.
    Couriel, Daniel R.
    Kaminski, Mark Stefan
    Hussein, Mohamad A.
    Yeganegi, Homa
    Vij, Ravi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [40] A Comparison of the Clinical Characteristics, Treatment Response and Survival of Patients With and Without Light Chain Glycosylation on their Monoclonal Protein in Patients Treated with Carfilzomib, Cyclophosphamide, Lenalidomide and Dexamethasone (KCRD) in the Myeloma XI Trial
    Giles, Hannah Victoria
    Kishore, Bhuvan
    Drayson, Mark
    Wright, Nicola
    Cook, Gordon
    de Tute, Ruth
    Kaiser, Martin
    Morgan, Gareth
    Jackson, Graham
    Pratt, Guy
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 121 - 121
12345